The objective of this translational research was to evaluate the potential of genome-wide DNA methylation status as a predictive biomarker for the effectiveness of anti-EGFR antibodies in the second-line treatment for patients with metastatic colorectal cancer. This evidence concerns the gene EGFR and metastatic colorectal cancer.